Crossmark

The Effects of NLY01, a Novel Glucagon-Like Peptide-1 Receptor Agonist, on Cuprizone-Induced Demyelination and Remyelination: Challenges and Future Perspectives

Crossref DOI link: https://doi.org/10.1007/s13311-023-01390-4

Published Print: 2023-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Gharagozloo, Marjan https://orcid.org/0000-0002-2166-4012
Galleguillos, Danny

Jank, Larissa

Sotirchos, Elias S.

Smith, Matthew D.

Garton, Thomas

Kumar, Swati

Hussein, Omar

Potluri, Saahith

Taylor, Michelle

Siu, Catherine

Mace, Jackson W.

Dawson, Ted

Dawson, Valina L.

Lee, Seulki

Calabresi, Peter A.
Funding

Funding for this research was provided by:

National Multiple Sclerosis Society (TA-2104-37423)

U.S. Department of Defense (W81XWH-19-1-0622)
License Information

Text and Data Mining valid from 2023-07-01

Text and Data Mining valid from 2023-07-01

Version of Record valid from 2023-10-23
More Information

This article is maintained by: Elsevier

Article Title: The Effects of NLY01, a Novel Glucagon-Like Peptide-1 Receptor Agonist, on Cuprizone-Induced Demyelination and Remyelination: Challenges and Future Perspectives

Journal Title: Neurotherapeutics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1007/s13311-023-01390-4

Content Type: article

Copyright: Copyright © 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.

Document is current

Any future updates will be listed below